Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May;19(5):1161-1167.
doi: 10.1111/jth.15294. Epub 2021 Mar 31.

Similarities and perspectives on the two C's-Cancer and COVID-19

Jecko Thachil  1 , Alok Khorana  2 , Marc Carrier  3   4
Affiliations

Similarities and perspectives on the two C's-Cancer and COVID-19

Jecko Thachil et al. J Thromb Haemost. 2021 May.

Abstract

COVID-19 continues to dominate the health-care burden in the twenty-first century. While health-care professionals around the world try their best to minimize the mortality from this pandemic, we also continue to battle the high mortality from different types of cancer. For the hemostasis and thrombosis specialist, these two conditions present some unusual similarities including the high rate of thrombosis and marked elevation of D-dimers. In this forum article, we discuss these similarities and provide some considerations for future research and therapeutic trials.

Keywords: COVID-19; D-dimer; anticoagulation; cancer; embolism; thrombosis.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
D‐dimer production in acute lung injury and malignancies. Fibrinolysis in both these cases occurs in the extravascular spaces and intravascularly created using BioRender tool
FIGURE 2
FIGURE 2
A suggested algorithm for management of thrombosis in patients with COVID‐19 and cancer. The first two sections are for patients who do not have clinical evidence of thrombosis but have increased risk for thrombosis. DOAC, direct oral anticoagulants; LMWH, low molecular weight heparin; RCT, randomized controlled trial
See this image and copyright information in PMC

References

    1. Thachil J., Longstaff C., Favaloro E.J., et al. The need for accurate D‐dimer reporting in COVID‐19: communication from the ISTH SSC on fibrinolysis. J Thromb Haemost. 2020;18(9):2408–2411. - PMC - PubMed
    1. Thachil J., Juffermans N.P., Ranucci M., et al. ISTH DIC subcommittee communication on anticoagulation in COVID‐19. J Thromb Haemost. 2020;18(9):2138–2144. - PMC - PubMed
    1. White D., MacDonald S., Bull T., et al. Heparin resistance in COVID‐19 patients in the intensive care unit. J Thromb Thrombolysis. 2020;50(2):287–291. - PMC - PubMed
    1. Thachil J., Lippi G., Favaloro E.J. D‐Dimer testing: laboratory aspects and current issues. Methods Mol Biol. 2017;1646:91–104. - PubMed
    1. Oliver M., Goubran M., Karathra J., Karkhaneh M., Wu C.M. A retrospective review of the appropriateness of D‐dimer ordering and interpretation using wells’ clinical probability criteria. Blood. 2020;136(1):28–29.